Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry

SIMPLE SUMMARY: Cutaneous squamous cell carcinoma (cSCC) is one of the most common malignancies of the skin with poor survival outcomes in advanced stages of the disease. Recent clinical trials demonstrated the efficacy of checkpoint-inhibitors (CPI) therapy for advanced stage disease, but there is...

Descripción completa

Detalles Bibliográficos
Autores principales: Haist, Maximilian, Stege, Henner, Lang, Berenice Mareen, Tsochataridou, Aikaterini, Salzmann, Martin, Mohr, Peter, Schadendorf, Dirk, Ugurel, Selma, Placke, Jan-Malte, Weichenthal, Michael, Gutzmer, Ralf, Leiter, Ulrike, Kaatz, Martin, Haferkamp, Sebastian, Berking, Carola, Heppt, Markus, Tschechne, Barbara, Schummer, Patrick, Gebhardt, Christoffer, Grabbe, Stephan, Loquai, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688854/
https://www.ncbi.nlm.nih.gov/pubmed/36428636
http://dx.doi.org/10.3390/cancers14225543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688854/
https://www.ncbi.nlm.nih.gov/pubmed/36428636
http://dx.doi.org/10.3390/cancers14225543

Ejemplares similares